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Abstract: A vegetarian diet has been associated with a lower risk of coronary artery disease (CAD).
Plasma triacylglycerols, ceramides, and phosphatidylcholines may improve prediction of recurrent
coronary events. We sought to investigate effects of a lacto-ovo-vegetarian diet (VD) on plasma lipidome
in CAD patients and simultaneously assess associations of plasma lipids with the extent of coronary
atherosclerotic burden. We analyzed 214 plasma lipids within glycerolipid, sphingolipid, and sterol lipid
classes using lipidomics from a randomized controlled, crossover trial comprising 31 CAD patients on
standard medical therapy. Subjects completed a four-week intervention with VD and isocaloric meat
diet (MD), separated by a four-week washout period. The VD increased levels of 11 triacylglycerols and
lowered 7 triacylglycerols, 21 glycerophospholipids, cholesteryl ester (18:0), and ceramide (d18:1/16:0)
compared with MD. VD increased triacylglycerols with long-chain polyunsaturated fatty acyls while
decreased triacylglycerols with saturated fatty acyls, phosphatidylcholines, and sphingomyelins than
MD. The Sullivan extent score (SES) exhibited on coronary angiograms were inversely associated
with triacylglycerols with long-chain polyunsaturated fatty acyls. Phosphatidylcholines that were
lower with VD were positively associated with SES and the total number of stenotic lesions. The VD
favorably changed levels of several lipotoxic lipids that have previously been associated with increased
risk of coronary events in CAD patients.
Keywords: coronary artery disease; randomized controlled trial; vegetarian diet; lipidomics
1. Introduction
Coronary artery disease (CAD) is a leading cause of morbidity and death worldwide [1]. A global
change in diet characterized by a reduction in caloric intake, higher intake of plant-based food, and a reduced
consumption of red and processed meat has the potential to prevent or delay the development of
non-communicable diseases [2]. Epidemiological studies have shown that a lacto-ovo-vegetarian diet
Nutrients 2020, 12, 3586; doi:10.3390/nu12113586 www.mdpi.com/journal/nutrients
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(VD) is associated with a 29% risk reduction in CAD mortality [3] and meta-analyses of randomized
controlled trials have shown that such a diet favorably affects CAD risk factors including total
cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C),
blood pressure, and body weight [4,5]. Although blood triacylglycerol (TG) level has also been
considered an independent risk factor for CAD, findings of randomized controlled trials regarding
effects of a vegetarian diet on its concentration remain inconsistent [4,6,7].
Molecular lipid species, including glycerolipids, phospholipids, sphingolipids, and ceramides
are involved in various biological functions including energy storage, serving as precursors for
metabolic processes and as main components of cellular building blocks [8]. Perturbations in lipid
metabolism can lead to lipotoxicity, generally defined as an increased concentration of detrimental
lipids such as specific lipids with saturated fatty acyls and ceramides [9]. Indeed, dysregulation of lipid
metabolism has often been reported in cardiovascular disease [10,11]. Recent large-scale lipidomics
analyses of epidemiological studies indicate that ceramides and phosphatidylcholines may improve
prediction of recurrent CAD events, independent of traditional CAD risk factors [10,11]. Dietary lipid
overload, in addition to disturbed adipose tissue metabolism play major roles in accumulation of
lipotoxic lipids [12].
We previously found that the extent of coronary atherosclerosis assessed by the Sullivan extent
score in CAD patients was associated with extra-coronary artery disease, all-cause mortality, and poor
prognosis following myocardial infarction [13]. It has been reported that the extent of coronary
atherosclerosis is positively associated with levels of total cholesterol and LDL-C, and inversely
associated with HDL-C. However, randomized controlled trials investigating effects of a vegetarian
diet on the lipid profile or on lipid metabolic pathways are lacking. Such information may be of
importance in identifying targets for CAD prevention and management using dietary approaches.
In a recent randomized open-labelled cross-over study, we reported that a 4-week VD improved
levels of oxidized low-density lipoprotein cholesterol and cardiometabolic risk factors including body mass
index (BMI), body weight, total cholesterol, and low-density lipoprotein cholesterol, compared with an
isocaloric meat-containing diet (MD) [14]. The goal of the current exploratory study was to determine
the effects of a VD on the plasma lipidome and to investigate associations between plasma lipids and
CAD burden, assessed by coronary angiogram from a recent percutaneous coronary intervention (PCI).
2. Materials and Methods
2.1. Study Participants
Subjects with CAD treated with PCI and on optimal medical therapy were recruited from patients
at the Department of Cardiology, Örebro University Hospital, Sweden, from September 2017 through
March 2018. The inclusion criteria were >18 years of age, stable CAD, PCI more than 30 days prior to
inclusion in the study, and receiving optimal medical therapy including cholesterol-lowering drugs
and aspirin. Exclusion criteria included age <18 years, unstable cardiovascular disease, PCI treatment
in the 30 days prior to inclusion, inability to provide informed consent, already following a vegetarian
or a vegan diet, vitamin B deficiency, known food allergy, previous surgery for obesity or gastric
bypass surgery, or life expectancy <1 year. All participants provided oral and written informed consent.
The primary outcome of this trial was to investigate difference in change in plasma oxidized LDL-C
between diets, which has been published elsewhere [14]. The sample-size calculation was based on
previous studies in which a VD or food supplements (nuts, soy-based cereal, cranberry juice) were
shown to reduce oxidized LDL-C by 10% compared to no intervention and was based on an estimated
10% dropout rate. A total of 31 subjects were enrolled [14].
2.2. Study Design
The flowchart of the study is presented in Figure 1. The study design has been described
previously [14]. In brief, the vegetarian diet in patients with ischemic heart disease (VERDI) trial was
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a prospective, randomized, open-labelled, cross-over study. Subjects consumed a four-week VD and
a four-week isocaloric diet with daily meat consumption, separated by a four-week washout period.
Participants were randomly allocated 1:1 to intervention sequences VD/MD or MD/VD. Data were
obtained at baseline, following the first intervention, at the end of the washout period, and following
the second intervention. The study is registered at ClinicalTrials.gov (NCT02942628) and the regional
ethical review board in Uppsala, Sweden approved the study (Dnr 2016/456). Clinical Trial Registration:
URL: https://www.clinicaltrials.gov; Unique identifier: NCT02942628.
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Figure 1. The workflow of study. CAD, coronary artery disease; MD, meat diet; VD, vegetarian diet.
2.3. Dietary Interventions and Compliance
Detailed information of diets has been described previously [14]. Subjects were provided with
ready-made frozen lunches and dinners based on traditional Swedish recipes, produced and supplied
by Dafgård, Källby, Sweden. The VD allowed intake of eggs and dairy products. We based the MD on
the av rage meat consumption in Sweden of approximately 145 g/day. Subjects were responsible for
weekly collection of the meals from the cardi logy department. At the first study visit, subjects met
with a research dietitian who provided instruction on strictly following the meal plans, which were
energy-adjusted based on subject’s basal metabolic rate and physical activity level according to Henry’s
equation. In addition to the two main meals provided, participants were asked to have breakfast and
two light snacks that were selected from provided options every day. The diet plans conformed to the
Nordic Nutrition Recommendations [15]. Nutrition calculation software (Dietist Net Pro; Kost och
Näringsdata AB, Bromma, Sweden) w s used to determine the nutrient composition of the diets.
A three-day weighed food record show both dietary interventions to be well-tolerated, and overall
adherence based on self-reported diaries was 88% for both interventions. Detailed information has
been presented elsewhere [14].
2.4. Measurements of Cardiovascular Risk Factors
Subject height was measured in centimeters at baseline. At the four study visits, the following
values were assessed: blood pressure and heart rate with a digital automatic sphygmomanometer in
the right arm after five minutes of seated rest; body weight in kilograms, with the participants dressed
in light clothing without shoes; BMI determined as weight in kilograms divided by height in meters
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squared; total cholesterol (TC), LDL-C, HDL-C, and total triglycerides assessed using a dry chemistry
standardized method. High sensitivity CRP (hs-CRP) was measured with two-site sandwich assays.
HbA1c was measured using high performance liquid chromatography [14]. Oxidized LDL-C was
assessed using an enzyme-linked immunosorbent assay kit (Mercodia, Uppsala, Sweden).
2.5. Assessment of Coronary Artery Disease Burden
We estimated the total CAD burden by eye balling visual analysis of coronary angiograms,
performed a median of 219 days prior to baseline (interquartile range 146–348) (Figure 1). The coronary
tree was divided into 15 segments as defined by the American Heart Association (Figure 2). In each
segment, we assessed stenosis diameter, number of stenotic lesions, and longitudinal extent of
atherosclerosis. The degree of stenosis in each segment was defined as the percentage of luminal
narrowing in the most severely stenosed lesion of each coronary segment. A non-narrowed section
approximately 5 mm proximal or distal to the stenotic lesion was used as reference to estimate
percentage of diameter stenosis. A significant stenosis was defined as >50% narrowing. The number
of stenotic lesions was counted in each segment. Any stenotic lesion extending twice the distance of
normal lumen diameter was considered two lesions. A maximum number of three stenotic lesions
was considered in each segment. We calculated the total number of stenotic lesions in all coronary
arteries. The branches distal to a stenosis >50% were assessed before and after PCI. Branches estimated
at <1 mm diameter were not included in the analysis.Nutrients 2020, 12, x FOR PEER REVIEW 5 of 17 
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right coronary artery, 2 = middle right coronary artery, 3 = distal right coronary artery, 4 = right
posterior descending artery, and 15 = left posterior descending artery; (C): 5 = left main coronary
artery, 6 = proximal left anterior descending artery, 7 = middle left anterior descending artery,
8 = distal left anterior descending artery, 9–10 = first and diagonal branches of left anterior descending
artery; (E): 11 = proximal left circumflex, 12 = obtuse marginal branch, 13 = distal left circumflex,
14 = posterolateral branch. (B): significant obstructive coronary artery disease with stenosis ~90%
(orange arrow) in segment 1; the longitudinal extent of atherosclerosis was ~70%. (D): Arrows from
right to left show ~40% (black), ~60% (white), ~60% (red), and ~40% (green) stenosis in segments
6, 7, 8, and 8, respectively. Longitudinal extent of atherosclerosis was ~80% in segment 6, ~90% in
segment 7, and ~80% in segment 8. (F): ~90% stenosis in segment 11 (yellow arrow) with estimated
~50% longitudinal atherosclerosis.
The Sullivan extent score (SES) was used to classify the longitudinal extent of CAD [16]. Coronary artery
disease was defined as irregularity of any vessel wall obstructing >20% of the total lumen and was
estimated relative to the total length of the studied segment. An occluded lesion in any segment was
defined as at least 50% longitudinal extent. The proportion of the longitudinal extent of each segment
occupied by the lesion was multiplied by a factor representing the surface area of the studied segment
relative to the entire coronary tree. The left main coronary artery accounted for 5%, the left anterior
descending artery 35%, the left circumflex artery 30%, and right coronary artery 30%, according to the
SES definition. A patient could hence have an SES value from 0 to 100.
2.6. Lipidomics Analysis
Venous blood samples were collected at the four study visits in evacuated plastic tubes and
centrifuged in a cooling system at 1560 g for 10 min at −40 ◦C and stored at −80 ◦C as plasma aliquots
prior to lipidomic analyses.
The order of plasma samples was randomized prior to extraction and analysis. Lipids were
extracted using a modified version of the Folch procedure [17]. Ten µL of 0.9% NaCl and organic
solvent (120 µL, 2:1 vol:vol chloroform:methanol) containing 2.5/mL µg of internal standard solution
was added to 10 µL of each plasma sample. Samples were vortex mixed and incubated on ice for
30 min, after which they were centrifuged at 9400× g for 3 min at 4 ◦C. Sixty µL from the lower lipid
layer of each sample was transferred to a glass vial with an insert, and 60 µL of chloroform:methanol
2:1, vol:vol was added to each sample. Extracted lipids from plasma samples were stored at −80 ◦C
until analysis and were randomized before analysis.
Chromatographic separation of 1 µL of the extracted samples was performed on an Agilent
1290 Infinity ultra-high-performance liquid chromatography system connected to an Agilent 6545
quadrupole time-of-flight mass spectrometer equipped with jet stream electrospray ionization.
The extracted samples were analyzed in positive electrospray ionization polarity mode (ESI+),
and MassHunter B.06.01 (Agilent Technologies, Santa Clara, CA, United States) was used for all
data analysis.
Data processing was performed using open-source software MZmine 2.3.4. Details of the mass
spectrometry (MS) data processing are shown in supplementary materials. Peaks were identified using
a custom database search and normalized using lipid class specific internal standards and MS/MS
data, as described [18]. Unknown lipids were normalized to the nearest eluting internal standard.
The custom database used in this study was recently assessed as part of the NIST lipidomics ring study,
comprising 31 laboratories worldwide [19]. Quality control was performed throughout the dataset by
including blanks, pure standard samples, extracted standard samples, and pooled plasma samples
from this study. Mean relative standard deviation for internal standards in all samples was 25.4%
(raw variation), and the mean relative standard deviation percent for the identified lipids in the pooled
samples (n = 5) was 15.6%. For the lipid species, fatty acyl chains were abbreviated Cx:y, where x
represents the number of carbon atoms and y the number of double bonds of the fatty acyl chain.
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2.7. Statistical Analysis
Statistical analyses were performed using R v. 3.6.1. Missing values (0.03%) were imputed
using random forest algorithm implemented in the R package missForest. Only identified lipids were
subjected to statistical analysis.
We applied a multilevel random forest algorithm implemented in the R package MUVR [20] to
investigate effects of diet on plasma lipidome. The multilevel analysis is applied to dependent data
structures in which different treatments are administered to the same subjects and has been successfully
used to exploit differences related to dietary intervention in cross-over studies [20]. All variables
were normalized to unit variance (z-scores). The number of components were selected based on
repeated double cross-validation, and significance of multivariate models was assessed by permutation
tests (n = 1000, Table S1). A common baseline effect was assumed for both interventions, since no
differences in plasma lipidome were observed between baseline and the end of the wash-out period
(Figure S1). We further assessed the effect of VD vs. MD on each target lipid using generalized linear
mixed models (R package lme4). Fixed factors included diet, sequence of diet allocation, and their
interaction, with baseline value as covariate and subject as random factor. Data were log2-transformed
before analysis, and p values were adjusted for multiple comparisons using the Benjamini-Hochberg
false discovery rate (FDR). A value of p < 0.05 was considered significant. We additionally assessed
differences from baseline in lipidome of each diet intervention (VD or MD).
To identify lipids with similar physiological and molecular characteristics that differed between
VD and MD, a co-expression network of lipids was constructed using the weighted gene correlation
network analysis (WGCNA) [21]. In brief, we calculated a correlation matrix containing all pairwise
Pearson’s correlations between lipids measured after intervention, first removing outliers to improve
data quality (Figure S2A). We then defined a signed hybrid network, and a power of 8 was selected
by the Scale-Free Topology criterion (model fitting index R2 > 0.8) (Figure S2B). The lipids were
hierarchically clustered using the distance measure, and modules were constructed by establishing
a height cutoff for the resulting dendrogram using a dynamic tree-cutting algorithm, with a minimum
module size of five. The resulting lipid modules were assigned color names and identified using the
eigenvector of each module, designated the module eigenlipid (ME), defined as the first principal
component of the standardized expression profiles, considered the best archetype of the standardized
module expression data. Twelve lipids were not grouped in any module (Figure S3). Differences in ME
between VD and MD were assessed by paired t tests.
We further assessed whether lipids that differed between VD and MD were associated with
CAD burden. First, a matrix of lipids that differed between VD and MD was calculated, normalized,
and entered into a principal component analysis to discern patterns and account for inter-correlations.
We determined the number of components according to the criteria of a very simple structure.
Associations between PCA scores based on lipidome data and CAD burden were analyzed using linear
regression adjusted for age, sex, and BMI measured at baseline. We investigated associations of plasma
lipids measured at baseline with CAD burden, using linear regression. In addition, we computed
Spearman correlation coefficients between lipid patterns and the clinical factors that differed between
VD and MD, including BMI, oxidized LDL-C, LDL-C, and TC.
3. Results
3.1. Characteristics of Participants
A total of 150 patients were assessed for eligibility, and 31 that agreed to participate in the
study were randomized 1:1 to either VD/MD or MD/VD. During the first intervention period one
participant from each diet group withdrew, and, during the second intervention period, a further
two participants withdrew, also one from each group. Thus, 27 completed both intervention periods.
Baseline characteristics of the study population in the VERDI trial are shown in Table 1. The majority
of study participants were male (n = 24) with a median age of 67 years and a median BMI of 27.5 kg
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m2. Before enrolment, 24 (77%) patients had experienced myocardial infarction, and eight (26%) had
been diagnosed with stable or instable angina. All study participants received statin therapy, and 94%
took aspirin.
Table 1. Baseline characteristics of VERDI study participants.
Characteristics All (n = 31) VD (n = 16) MD (n = 15)
Age years, median(range) 67 (63–70) 67 (65–70) 68 (61–70)
Sex, male, n (%) 29 (94%) 15 (94%) 14 (93%)
Myocardial infarction, n (%) 24 (77%) 6 (63%) 6 (93%)
Angina, n (%) 8 (26%) 7 (44%) 1 (7%)
Diabetes mellitus type 2, n (%) 2 (7%) 2 (13%) 0 (0%)
Hypertension, n (%) 17 (55%) 10 (63%) 7 (47%)
BMI, kg/m2 28 ± 2.9 28 ± 3.3 27 ± 2.5
Systolic Bp, mm Hg 139 ± 17.4 140 ± 17.4 138 ± 18.0
Diastolic Bp, mm Hg 87 ± 9.6 88 ± 10.6 87 ± 8.7
Total cholesterol, mmol/L 3.5 ± 0.6 3.5 ± 0.73 3.4 ± 0.44
LDL-C, mmol/L 1.6 ± 0.4 1.6 ± 0.5 1.6 ± 0.4
HDL-C, mmol/L 1.3 ± 0.3 1.3 ± 0.4 1.2 ± 0.2
Triacylglycerol, mmol/L 1.1 ± 0.3 1.1 ± 0.4 1.1 ± 0.3
eGFR, mL/min per 1.73 m2 76.4 ± 9.7 75.1 ± 7.6 77.7 ± 11.7
HbA1c mmol/mol, median (range) 39 (36–40) 39 (36–42) 39 (36–40)
Hs-crp mg/L, median (range) 0.7 (0.5–1.7) 0.8 (0.4–1.7) 0.7 (0.4–1.7)
Statin, n (%) 31 (100%) 16 (100%) 15 (100%)
Ezetimibe, n (%) 7 (23%) 4 (25%) 3 (20%)
ASA, n (%) 29 (94%) 15 (94%) 14 (93%)
P2y12 inhibitors, n (%) 20 (65%) 8 (50%) 12 (80%)
Beta-blockers, n (%) 28 (90%) 14 (88%) 14 (93%)
ACE inhibitors/ARBs, n (%) 27 (87%) 13 (81%) 14 (93%)
CCB, n (%) 11 (36%) 6 (38%) 5 (33%)
Data are presented as median [interquartile range], n (%) or mean ± standard deviation. ACE inhibitors/ARB,
angiotensin converting enzyme inhibitors or angiotensin II receptor blockers; ASA, acetylsalicylic acid; Bp, blood pressure;
CCB, calcium channel blockers; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-C,
high-density lipoprotein cholesterol; Hs-CRP, high-sensitivity c-reactive protein; LDL-C, low-density lipoprotein
cholesterol; mmHg, mm of mercury; P2Y12 inhibitors, clopidogrel or ticagrelor.
The baseline characteristics of the participants relative to number of stenotic lesions in the coronary
arteries and SES are shown in Supplemental Table 1. The SES and the number of stenotic lesions in the
coronary arteries were strongly correlated (r = 0.80, p < 0.001), and also correlated with systolic blood
pressure (r = 0.34, p < 0.05), BMI (r = -0.49, p < 0.001), and weight (r = -0.41, p < 0.001). Subjects with
≥4 stenotic lesions compared to those with <4 stenotic lesions had significantly lower Hba1c levels.
Individuals with SES > 18 were older and had lower weight than those with SES ≤ 18.
3.2. Plasma Lipidome
In total, 214 lipids were identified, including 81 glycerolipids (80 triacylglycerols (TG) and
1 diacylglyceride (DAG)); 95 glycerophospholipids (55 phosphatidylcholine (PC), 2 phosphatidylglycerols
(PG), 3 phosphatidylinositols (PI), 7 phosphatidylethanolamines (PE), 19 alkylphosphatidylcholines
(O-PC), 7 lyso-phosphatidylcholines (LPC)); 33 sphingolipid (22 sphingomyelins (SM), 8 ceramides
(Cer), 2 hexosylceramides (HexCer), 1 lactosylceramides (LacCer)) and 7 sterol lipid classes (7 cholesteryl
esters (CE)) (Table S2).
The plasma lipid profiles differed significantly with diet, with a misclassification rate of 96%
(Figure S4). Plasma levels of 41 lipids differed significantly in VD and MD (Figure 3), including 18 TGs,
12 O-PCs, 6 PCs, 2 PEs, LPC (16:0), CE (18:0), and Cer (d18:1/16:0) when assessed using univariate
statistics (FDR p < 0.05, Table S3). Specifically, compared with the MD, the VD resulted in higher levels
of 11 TGs and lower levels of 7 TGs, 9 O-PCs, 5 PCs, two PEs, CE (18:0), Cer (d18:1/16:0), and LPC
(16:0). Plasma levels of 64 lipids significantly differed from baseline after VD, while 11 differed from
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baseline with MD (FDR p < 0.05, Figure S5, Table S3). Lipids showing greatest difference between diets
were TGs, PCs, and O-PCs.Nutrients 2020, 12, x FOR PEER REVIEW 9 of 17 
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Figure 3. The effect of diet on plasma lipid profiles. Plasma lipids significantly differed between the
vegetarian and meat diet by generalized linear mixed modelling (FDR p < 0.05). Standardized values of
least-squares mean with 95% confidence intervals are presented for comparison. TG, triacylglycerols;
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DAG, diacylglyceride; PC, phosphatidylcholine; PG, phosphatidylglycerol; PI, phosphatidylinositol;
PE, phosphatidylethanolamine; O-PC, alkylphosphatidylcholines; LPC, lyso-phosphatidylcholine;
SM, sphingomyelin; Cer, ceramides; CE, cholesteryl ester. # Lipids with same fatty acyl chains (Cx:y)
were presented in the dataset, where x represents the number of carbon atoms and y the number of
double bonds of the fatty acyl chain.
We further clustered lipids into co-expression modules to identify those with similar physiological
and molecular characteristics and reduce the dimensions of the lipidomics data, clustering 202 of
214 lipids into 12 modules. Each module was, in general, dominated by lipids of the same class (Figure 4,
Table S2). Compared with MD, the VD resulted in lower level of eigenlipid modules dominated by
PCs (MEyellow and MEturquoise), SMs (MEturquoise), and TGs with a median of one unsaturated
carbon/carbon bond (MEmagenta) and a greater level of eigenlipid modules including large numbers
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Index Size Enriched species TAG (CN, 
DBC)
MEred 10 TAG(10) 55,4
MEblue 33 TAG(28),DG(1),PC(4) 52,3





MEbrown 23 TAG(21),PC(1),LPC(1) 49,1
MEmagenta 8 TAG(7),PC(1) 52,1










Age BMI W ight Oxidized LDL-C TC LDL-C HDL-C TAG
A
B
Spearman correlations between module eigenlipids and cardiovascular risk factors 
Figure 4. Co-expression modules of lipids determined by the weighted gene correlation network
analysis. Module size, lipid species, and range of total number of carbons (CN) and number of
double bonds (DBC) of TG (A, right), Spearman’s correlation coefficient between modules and
cardiovascular risk factors (A, left), and difference in eigenlipid of modules between VD and MD
(B). Cer, ceramide; CE, cholesteryl ester; DAG, diacylglyceride; HDL-C, High-density lipoprotein
cholesterol; HexCer, hexosylceramide; LacCer, lactosylceramide; LDL-C, low-density lipoprotein
cholesterol; LPC, lyso-phosphatidylcholine; O-PC, alkylphosphatidylcholines; PC, phosphatidylcholine;
PE, phosphatidylethanolamine; PG, phosphatidylglycerol, PI, phosphatidylinositol; SM, sphingomyelin;
TG, triglyceride.
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Of note, WGCNA-modules that differed in VD and MD were significantly correlated with
cardiovascular risk factors that were lower after VD than after MD (Figure 4, Table S4). Specifically,
the module of SMs (MEturquoise) was positively correlated with oxidized LDL-C, LDL-C, and TC,
while it was inversely correlated with BMI and bodyweight. The module of PCs (MEyellow) strongly
correlated with TC. The module mainly comprised of ceramides (MEblack), showed strongest correlation
with oxidized LDL-C (r = 0.37, p = 0.007) compared to other modules, but did not differ between VD
and MD.
3.3. Associations between Plasma Lipids and Coronary Artery Disease Burden
Principle components analysis was applied on 74 lipids that differed between VD and MD
(p < 0.05, Table S3) to account for the inter-correlations among lipids (correlation range −0.51 to 0.85).
Four components accounted for 64% of the total variance in lipid levels (Table 2). We observed an inverse
association of the SES with the lipidome PCA component 2, representing long-chain polyunsaturated
TGs, which were higher after the VD than after MD. The PCA component 4, comprising PCs that were
reduced in VD compared with MD, was positively associated with SES and the total number of stenotic
lesions. Significant correlations of the PCA components and the certain characterized lipid species
with VD-induced reduction of LDL-C and TC were also observed (Table 2, Table S5).
Table 2. Associations between of orthogonal lipids pattern described by principal components derived









Associations with CAD burden (β-coefficient ± SE)
Sullivan extent score 0.05 ± 0.06 −0.25 ± 0.10 * −0.24 ± 0.23 0.87 ± 0.51 *
Number of stenotic lesions −0.005 ± 0.02 −0.02 ± 0.04 −0.008 ± 0.08 0.31 ± 0.16 *
Association with cardiometabolic risk factors that were improved after VD
Oxidized LDL-C 0.08 −0.14 0.45 * −0.12
LDL-C 0.02 −0.60 * 0.30 * −0.13
TC 0.09 −0.59 * 0.31 * −0.08
BMI 0.31 * 0.16 0.21 −0.07
Associations of baseline lipids with the Sullivan extent score (SES) and the total number of stenotic lesions were
assessed using linear regression adjusted for age, sex, BMI, and total cholesterol. The β-coefficient and standard
error obtained from linear regression are presented. * denotes significant association (p < 0.05).
In addition, we found baseline levels of 10 lipids that were associated with the total number of
stenotic lesions and six associated with the SES (Tables S6 and S7). Among these, PE (O-38:5), PC (36:1),
PC (38:1), and PC (39:6) were associated with both values. No association remained significant after
correction for multiple testing.
4. Discussions
In this crossover randomized dietary intervention study in CAD patients on standard medical
therapy, a four-week VD showed significant impact on plasma lipids, in particular TGs, PCs, O-PCs,
and SMs, compared to an isocaloric MD. Lipid clusters dominated by TGs and PCs were positively
correlated with VD-induced improvements in cardiometabolic risk factors. We found that favorable
changes in long-chain polyunsaturated containing TGs induced by VD were inversely associated
with CAD burden, which has not been previously reported. Our findings indicate that the VD led to
alteration in level of several plasma lipotoxic lipids associated with subclinical coronary artery disease
and development of recurrent coronary artery events.
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4.1. Diet Effects on Plasma Lipidome
An elevated level of fasting blood triglycerides has been considered an independent risk factor
for CAD [22], but findings of randomized controlled trials regarding the effects of plant-based diet
on blood triglycerides are inconsistent [4,6,7]. Our initial analysis of data of the current trial did not
show difference in total TG between VD and MD [14]. To our knowledge, no previous study has
been reported where the impact of a vegetarian diet on the quality of triglycerides and its proportions
of saturated, monounsaturated, and polyunsaturated fatty acyl content was evaluated. Our data
using high-throughput lipidomics clearly showed the VD to result in higher levels of long-chain and
polyunsaturated TGs and lower levels of lipotoxic lipids, such as TGs with saturated fatty acyl chains
as well as and specific species of ceramides than observed with MD. In a primary preventive cohort of
685 healthy individuals, short-chain saturated fatty acyl chains of TGs were found to be associated
with higher risk of cardiovascular diseases development [23]. It has also been reported that CAD
patients exhibited lower levels of unsaturated TGs in the epicardial adipose tissue than people without
CAD [24]. We found TGs containing linoleic acid to be higher after the VD than after MD. Studies have
shown inverse associations of high levels of circulating phospholipids containing linoleic acid with
CAD mortality [25] and subclinical CAD [26,27].
Our findings highlight the need to address the effect of TG species separately, as opposed to
the total blood triglyceride concentration. The measure of total TGs, rather than the assessment of
individual components as conducted in the present study, may explain inconsistent conclusions
regarding effects of vegetarianism on blood triglycerides in the literature.
We found that diet interventions affected levels of several glycerophospholipids, in particular
PCs, PEs, LPCs, and SMs. These lipid species are the main constituents of cell membranes and are
also involved in signal transduction and various physiological functions and have been associated
with development of CAD and its risk factors [28,29]. Compared with the MD, the four-week VD
was associated with lower levels of PCs and SMs containing fatty acyl chains C38:5, C38:6, C32:0,
C16:0, and C24:1, which are associated with CAD risk and cardiovascular mortality [23,28,29]. The VD
also resulted in lower levels of several alkylphospholipids (O-PC) species than MD and compared to
baseline. Alkylphospholipids have been reported to be inversely associated with multiple metabolic
diseases [30–32]. Meanwhile, Meikle et al. [33] observed that postprandial levels of ether-linked
phospholipids increased after a dairy meal but decreased after a soy-based meal. Further studies are
required to elucidate whether modulation of alkyl-phosphatidylcholine levels by drugs or diet could
have beneficial effects on CAD.
Ceramides are known to affect several metabolic processes linked to CAD, including LDL
aggregation and uptake, endothelial dysfunction, and multiple inflammatory processes [10,34].
The ceramide species Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:1), and Cer(d18:1/24:0) have
been shown predictive of cardiovascular events, especially cardiovascular death, independent of
traditional risk factors [10,11]. Assessment of ceramide biomarkers has been introduced into clinical
practice at the Mayo clinics to assess risk of CAD events [35]. We observed lower Cer(d18:1/16:0)
levels with the VD than with MD. In addition, lower levels of Cer(d18:1/16:0), Cer(d18:1/22:0),
HexCer(d18:1/22:0), LacCer(d18:1/16:0) were observed after VD than at baseline, partly supporting its
benefits in management of cardiovascular disease.
The VD improved the plasma lipid profile predominately by reducing levels of lipotoxic lipid
species associated with adverse cardiometabolic health outcomes such as TGs with saturated fatty acyls
and certain species of glycerophospholipids, and ceramides. The VD caused higher levels of long-chain
polyunsaturated TGs that have been reported associated with beneficial cardiometabolic outcomes.
4.2. Associations of Plasma Lipids with Coronary Artery Disease Burden
We found lipid species that differed between VD and MD to be associated with CAD burden,
as well as with CAD risk factors improved by VD, including BMI, oxidized LDL-C, LDL-C, and TC [14].
These results are in agreement with previous studies showing an association of elevated lipoprotein(a)
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and LDL-C with CAD burden as assessed by the SES [36], and other coronary risk scores [37,38].
Importantly, we found that long-chain polyunsaturated TGs, which were higher after VD compared
with MD, to be inversely associated with SES in CAD patients. Several PCs that were lower after VD
than after MD were associated with a greater CAD burden as assessed by the total number of stenotic
lesions. Our findings strengthen the hypothesis of benefits of VD for prevention of CAD events via
modulation of the lipid profile.
Participants with a higher SES had lower body weight than those with lower scores. Previous studies
have indicated that overweight patients undergoing PCI have better clinical outcomes compared to lean
or normal weight patients [39]. However, this may be a result of reverse causation and confounding
by smoking [40]. We found that participants with a higher SES were more likely to have a history
of myocardial infarction than stable/unstable angina, suggesting that lower weight in this group of
patients might have been due to reverse causality.
4.3. Strengths and Limitations
The strengths of the reported study include its cross-over design, well-characterized subjects
receiving standard medical therapy, and a high rate of study completion. The applied untargeted
lipidomics covered a wide range of lipid species, enabling us to investigate distinct impacts of diet
intervention on different lipid species. Moreover, the present cross-over study design reduces the
likelihood of bias and we estimated that any potential confounders (e.g., estimated glomerular filtration
rate indicating renal function, diabetic status, statin or ezetimibe treatment) will be equally distributed
in each sequence (MD-VD vs. VD-MD). Further strengths are comprehensive statistical analyses,
including both traditional and machine learning methods including multivariate statistics (supervised
multilevel random forest, WGCNA network analysis, and unsupervised principal component analysis)
and univariate analysis, allowing identification of lipid clusters associated with diet intervention,
cardiometabolic risk factors, and CAD burden. Of note, by using multilevel modelling particular
designed to analyze dependent data structures in which different treatments are administered to
the same subjects, we could successfully exploit within-individual variation in lipidome related to
dietary intervention.
Limitations include small study size and the few women subjects which may decrease
generalizability. The lipidomics approach applied in this study cannot provide absolute concentrations
of lipid species in plasma. Although there are constant advances in lipid analysis, complete lipidome
analysis remains challenging. Our study included relative concentrations of 214 lipids in five classes.
However, we cannot exclude the possibility that our lipidomics approach may have failed to detect
other lipids that could be affected by VD. Atherosclerotic burden was visually assessed without
absolute quantification and with no invasive versus noninvasive evaluation. However, the two
scores for assessing the atherosclerotic burden were highly correlated and consistent results were
obtained regarding associations between plasma lipids and scores, supporting that the quantitative
measurements were adequate. Although studies repeatedly showed significant protective effects
of a vegetarian diet on CVD prevention [41–43], vegetarian diets may cause mineral deficiencies,
e.g., iron, calcium, and zinc [44]. Previous studies have shown the associations between abnormal
mineral metabolism and high risk of CVD [45,46], particularly in patients with chronic kidney disease.
However, such health risks of vegetarian diets greatly depend on the types and amounts of foods
actually consumed, which should be further explored. Additionally, the dietary interventions were
relatively short (two months) and we did not have any data on long-term results (i.e., if any of the
subjects turned vegetarian), which is of great interest.
5. Conclusions
Our exploratory analysis of the randomized, cross-over study revealed that a VD compared
with a diet including daily meat consumption improved plasma lipid profiles, in particular TGs, PCs,
O-PCs, and SMs in CAD patients on standard medical therapy. The levels of plasma lipotoxic species
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(PCs, O-PCs, and saturated TGs), associated with increased risk of metabolic disease, were lower
after a VD compared with MD. Contrastingly, VD increased TGs with long-chain polyunsaturated
fatty acyls that were found to be inversely associated with CAD burden. Our results support the
hypothesis that a VD may be beneficial for secondary prevention of CAD via modulation of lipid
profiles. Future studies of larger size are warranted to confirm the findings of alterations of lipid
profiles by a vegetarian diet.
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